Dynamic Technology Lab Private Ltd Makes New Investment in Twist Bioscience Co. (NASDAQ:TWST)

Dynamic Technology Lab Private Ltd acquired a new position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,248 shares of the company's stock, valued at approximately $599,000.

Several other institutional investors and hedge funds have also recently modified their holdings of TWST. Thrivent Financial for Lutherans bought a new stake in shares of Twist Bioscience during the third quarter valued at approximately $43,992,000. Point72 Asset Management L.P. raised its stake in shares of Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company's stock valued at $33,168,000 after acquiring an additional 613,057 shares in the last quarter. Fred Alger Management LLC raised its stake in shares of Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company's stock valued at $32,272,000 after acquiring an additional 575,080 shares in the last quarter. Victory Capital Management Inc. raised its stake in Twist Bioscience by 4,133.1% in the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company's stock worth $15,187,000 after buying an additional 300,891 shares in the last quarter. Finally, Farallon Capital Management LLC bought a new position in Twist Bioscience in the second quarter worth approximately $9,462,000.

Analysts Set New Price Targets

TWST has been the subject of a number of recent research reports. Leerink Partners boosted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research note on Thursday, October 17th. TD Cowen reissued a "buy" rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. Scotiabank boosted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 19th. Finally, Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

Insider Activity

In related news, CEO Emily M. Leproust sold 14,334 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the transaction, the chief executive officer now directly owns 589,552 shares in the company, valued at $26,294,019.20. The trade was a 2.37 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dennis Cho sold 659 shares of the business's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04. Following the transaction, the insider now owns 94,481 shares of the company's stock, valued at $3,926,630.36. This represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock valued at $4,391,151 over the last ninety days. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Stock Up 1.8 %

Shares of TWST traded up $0.86 during trading hours on Friday, reaching $49.18. 508,411 shares of the company traded hands, compared to its average volume of 948,382. The stock has a market capitalization of $2.92 billion, a P/E ratio of -13.42 and a beta of 1.78. Twist Bioscience Co. has a 12-month low of $23.25 and a 12-month high of $60.90. The business has a fifty day moving average price of $43.78 and a 200-day moving average price of $46.23.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.